Nat Rev Clin Oncol
manufacturing, and customer need for amorphous solid dispersion (ASD) by spray drying a critical technology that improves drug solubility, bioavailability, and stability makes this expansion essential in order to meet the need for more innovative therapeutics
Obesity Three of the GLP-1 RAs are FDA approved for obesity: liraglutide (Victoza, Saxenda), semaglutide (Ozempic, Wegovy), and tirzepatide (Mounjaro, Zepbound) (these have separate brands for diabetes and obesity, and we have listed the diabetes brand first)
Plan your semaglutide refills and other eligible medical expenses strategically to maximize your annual FSA benefit
1999 Feb;13(2):411-8
Over the past five years, the global weight-loss drug market has evolved from GLP-1 single-target to dual-target therapies, driving peptides from early research into large-scale commercial development